Active surveillance (AS) is a treatment option for men with very low-risk prostate cancer (PCa); however, favorable outcomes achieved for men in AS are based on cohorts that under-represent African American (AA) men. To explore whether race-based health disparities exist among men with very low-risk PCa, we evaluated oncologic outcomes of AA men with very low-risk PCa who were candidates for AS but elected to undergo radical prostatectomy (RP).
INTRODUCTION
Up to 19% of men with newly diagnosed prostate cancer have characteristics of very low-risk disease, defined by the National Comprehensive Cancer Network (NCCN) as prostate-specific antigen (PSA) Ͻ 10 ng/mL, PSA density Յ 0.15 ng/mL/cm 3 , clinical stage Յ T1c, Gleason sum Յ 6, positive cores Յ 2, and cancer involvement per core Յ 50%. [1] [2] [3] Currently, NCCN encourages active surveillance as the preferred treatment option for very low risk patients with life expectancies of less than 20 years because it potentially reduces overtreatment of indolent cancers while allowing for curative intervention if disease progression is detected. Indeed, oncologic outcomes for men in active surveillance cohorts are favorable. Among several major surveillance cohorts, the chance of progression by grade on subsequent biopsy is 2.5% to 28%, and 10-year diseasespecific survival is 97% to 100%. 4 A key limitation of these encouraging results, however, is their generalizability to minority populations including African American (AA) men. For example, 90% of the 1,050 men in our institutional active surveillance program are white, with African Americans accounting for only 6.5% (69 men). Similarly, only 24 (9.6%) of 249 men in the University of
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
Miami active surveillance cohort are AA. 5 Because AA men have a higher age-adjusted prostate cancer incidence (1.6 times) and poorer oncologic outcomes following primary treatment, 6 it is imperative to determine the pathologic and oncologic outcomes of AA men with very low-risk prostate cancer to assess their suitability for active surveillance.
Among AA men with favorable disease characteristics, there are conflicting data regarding prostate-cancer outcomes. One study of 53 low risk African Americans (PSA, Յ 10 ng/mL; clinical stage, Յ T1c; Gleason sum, Յ 6; positive cores, Յ 2) who underwent radical prostatectomy at the University of Pennsylvania found that they had fared no worse than white patients regarding positive surgical margins, seminal vesicle invasion, pathologic upgrading, and biochemical recurrence. 7 In contrast, another study of 24 very low-risk AA men (clinical stage, Յ T2a; Gleason sum, Յ 6; positive cores, Յ 2; cancer involvement per core, Յ 20%) who are part of the active surveillance cohort at the University of Miami found that patients whose disease progressed by grade or volume were more likely to be AA and that AA race was an independent predictor of disease progression on active surveillance. 5 The factors that result in these divergent observations are unclear and may be influenced by the limited sample sizes used in these analyses.
Knowledge of potential health disparities among AA men with very low-risk prostate cancer is key to assess appropriateness for disease monitoring by active surveillance and to properly inform patients of the risks of surveillance and expected outcomes at surgery. Because of the limited information on African Americans in active surveillance, we sought to determine if oncologic outcomes for African Americans who were candidates for active surveillance but elected to undergo immediate radical prostatectomy were comparable to those of white patients and patients of other races.
PATIENTS AND METHODS
We retrospectively analyzed a database of 19,142 men who had undergone radical prostatectomy at Johns Hopkins since 1992 (PSA era). Men who received neoadjuvant hormonal treatments (n ϭ 833) were excluded from analysis. We studied 1,801 men who had very low-risk disease as defined by NCCN criteria (clinical stage, Յ T1c; biopsy Gleason sum, Յ 6; number of positive biopsy cores, Յ 2; maximum percent core involvement, Յ 50; PSA, Ͻ 10 ng/mL; and PSA density, Յ 0.15 ng/mL/cm 3 ). PSA density was calculated using preoperative serum PSA and pathologic prostate weights. 8 Minimum follow-up after surgery included yearly symptom assessment and PSA measurements. For men who did not receive follow-up at Johns Hopkins, yearly data were mailed in from patients and referring institutions. Biochemical failure was defined as a postoperative PSA Ն 0.2 ng/mL. For the entire cohort, mean and median follow-up was 4.4 and 3.0 years, respectively.
We analyzed a subset of men who reflected modern clinical practice: extended sampling at diagnosis (Ն 10 biopsy cores) in the contemporary Gleason grading era (2004 to present). The modern Gleason grading system is based on The International Society of Urological Pathology consensus scheme that assigns cribriform glands and ill-defined glands with poorly formed lumina to pattern 4 instead of pattern 3. 9 Patient biopsy samples were reviewed at Johns Hopkins, and radical prostatectomy specimens were processed as previously described and were analyzed centrally by genitourinary pathologists.
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In addition to standard measures of cancer control, we evaluated rates of adverse pathologic findings, defined as pT2 and Ն G4 ϩ 3, or pT3a and G3 ϩ 3 and PSM, or pT3a and Ն G3 ϩ 4, or Ն pT3b.
3, 11 We also studied predictive outcomes based on the Cancer of the Prostate Risk Assessment Post-Surgical scoring system (CAPRA-S), a validated predictor of biochemical recurrence that ranges from 0 to 12 points based on serum PSA, pathologic Gleason pattern, lymph node involvement, extracapsular extension, seminal vesicle invasion, and positive surgical margins. We defined increased/higher recurrence risk in this cohort as a CAPRA-S Ն 3, which is associated with a 27.2% or higher 5-year risk of recurrence.
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Median values of continuous variables were compared using t tests and by Wilcoxon-Mann-Whitney rank-sum tests for non-normally distributed variables. Proportions were tested by 2 tests and by Fisher's exact tests for variables with low expected event frequencies. Univariate and multivariable logistic regression analyses were used to model adverse pathologic findings, high pathologic risk scores (CAPRA-S Ն 3), and upgrading at prostatectomy. The level of statistical significance was predefined at P Ͻ .05 (two-tailed). To correct for multiple comparisons, the Bonferroni correction was applied: P values were considered significant if less than .025 in Tables 1 and 2 ; P values were considered significant if less than .0125 in Figure 1A and less than .01 in Figure 1B . Multivariable regression analyses were performed including all variables studied on univariate analyses: race, preoperative PSA, prostate weight, age, family history, percent positive biopsy cores, maximum percent cancer involvement per core, body mass index (BMI), and Charlson comorbidity index. This study was approved by the institutional review board. Statistical analyses were performed with Stata 11.0 (StataCorp, College Station, TX).
RESULTS
Preoperative characteristics between the cohorts of very low-risk white men (n ϭ 1,473) and AA men (n ϭ 256) were similar, with African Americans having slightly worse Charlson comorbidity scores ( Table 1) . Examination of pathologic parameters revealed that AA men had a lower rate of organ-confined cancers (87.9% v 91.0%; P ϭ .004) and a higher rate of Gleason upgrading (27.3% v 14.4%; P Ͻ .001). Furthermore, African Americans demonstrated a significantly higher hazard of biochemical recurrence (4.0% v 1.4%; log-rank P ϭ .004). Adverse pathologic findings were more common in AA patients than white patients (14.1% v 7.7%; P ϭ .001). Also, the rate of increased pathologic risk score (CAPRA-S Ն 3) was also significantly higher in African Americans (14.8% v 6.9%; P Ͻ .001). With a median follow-up of 3.0 years (AA patients, 2.0 years; white patients, 4.0 years), there were no differences in metastasis-free, cancer-specific, or overall survival.
Men of other races (neither white nor AA) were analyzed as a separate category. Seventy-two men were classified as very low risk and presented with overall characteristics similar to white men (Table 1) . Of note, the rate of upgrading was higher in non-AA, non-white men compared with white men alone (23.6% v 14.4%; P ϭ .032), though this finding was not statistically significant after the Bonferroni correction was taken into consideration. Rates of adverse pathology, higher CAPRA-S scores (Ն 3), and BCR did not differ between the two groups (P ϭ .821, P ϭ .647, and P ϭ .711, respectively).
To reflect modern clinical practice, we analyzed a cohort of only men with extended biopsy sampling (Ն 10 cores) in the era of modern Gleason grading, adopted by Johns Hopkins in 2004. This cohort consisted of 223 white patients, 101 AA patients, and 35 patients of other races. In this group, baseline and preoperative disease characteristics were similar between AA patients, white patients, and patients of other races (Table 2) . However, compared with white men, AA men continued to experience higher rates of upgrading (32.7% v 12.6%; P Ͻ .001), positive margins (19.0% v 6.3%; P ϭ .001), adverse pathology (19.8% v 7.2%; P ϭ .001), and higher pathologic risk score (CAPRA-S, Ն 3; 21.0% v 5.7%; P Ͻ .001). The distribution of CAPRA-S scores for this cohort are shown in Figure 1 .
Furthermore, the 101 AA men in the contemporary extendedsampling cohort were compared to determine whether AA race was an independent predictor of adverse oncologic outcomes using multivariable modeling after adjustment for preoperative parameters known to influence pathologic outcomes and disease recurrence. 13, 14 Because of the small cohort of men of other races and the overall similarity of their results with those of the white patients, AA men were compared with a referent group composed of 258 men (223 white men and 35 men of other races).
AA race was an independent predictor of adverse pathology (adjusted odds ratio [OR], 3.23; P ϭ .03; Table 3), higher pathologic risk CAPRA-S score (Ն 3; adjusted OR, 6.57; P ϭ .001; Table 4), and upgrading at prostatectomy (adjusted OR, 2.26; P ϭ .03; Table 5 ). ‫ء‬ P value derived from Wilcoxon-Mann-Whitney test. †P value derived from Fisher's exact test. ‡Adverse pathologic findings: pT2 and Ն G4 ϩ 3 or pT3a and G3 ϩ 3 and PSM or pT3a and Ն G3 ϩ 4 or Ն pT3b.
DISCUSSION
Active surveillance is the preferred treatment option for men with very low-risk prostate cancer and a life expectancy Յ 20 years. 1 However, these recommendations have been made based on retrospective reviews and prospective trials of primarily white men. Our study suggests that broad application of these recommendations may not be suitable for African Americans. Namely, we demonstrate that African Americans meeting NCCN criteria for very low-risk disease were more likely to sustain adverse oncologic outcomes (Gleason upgrading, adverse pathology, positive surgical margins, and biochemical recurrence) than white men or men of other races.
Multiple retrospective studies have shown that prostate cancer may be more aggressive in AA men in terms of incidence, presenting stage and grade, pathologic outcomes, recurrence after treatment, and mortality.
6,15-25 The reasons for this are unclear. As summarized in a review by Chornukur et al, 26 a component of these outcomes may be social and economic. African Americans with prostate cancer, overall, have lower socioeconomic status and levels of education, are less likely to be insured, and are less likely to undergo radical prostatectomy. Another component may be biologic. Using the SEER cohort and institutional prostatectomy data, Powell et al 27 have suggested African Americans harbor faster growing cancers that become high grade more frequently, and that the prevalence of distant metastases in African Americans with prostate cancer is fourfold higher than in white patients.
However, it is not clear whether AA outcomes are worse when selecting only men with favorable disease characteristics at diagnosis. 5, 7 These data are clinically important because men with favorablerisk disease choosing between definitive treatment or monitoring their disease via active surveillance need to be informed of the risks and expected outcomes of their decisions, especially if those outcomes were to vary significantly by race. In addition, racial disparities in outcomes of very low-risk disease may pose barriers to widespread application of active surveillance in appropriate patients.
Resnick et al 7 found no differences in outcomes after surgery (pathologic stage, upgrading, and recurrence) when comparing AA and white patients within a cohort of men with low risk prostate cancer. In that study, which included men from 1991 to 2007, stringent low risk was defined as PSA Յ 10, clinical stage Յ T1c, Gleason sum Յ 6, and positive cores Յ 2, as adapted from the University of Toronto active surveillance criteria. It is possible that the sample size of AA men (n ϭ53) was not large enough to detect a difference potentially suggested by higher upgrading at radical prostatectomy in AA men (32% v 24%; P ϭ .19). The rate of upgrading was similar to what very low-risk African Americans experienced at our institution (27.3% to 32.7%) though far higher than what white men experienced (12.6% to 14.4%). This may be related to the selection of our cohort by PSA density Յ 0.15 ng/mL/cm 3 as part of our very low-risk criteria.
Iremashvili et al 5 reported that among 24 AA men in the University of Miami active surveillance cohort African Americans were more likely to experience disease progression on surveillance and that AA race was an independent predictor of progression on surveillance after controlling for number of positive biopsy cores, prostate volume, and PSA density. The criteria for active surveillance in this cohort (1994 to 2011) were clinical stage Յ T2a, Gleason sum Յ 6, positive cores Յ 2, and cancer involvement per core Յ 20%. Though the interpretation of the results is limited by the small sample size and inclusion of patients before the contemporary system Gleason grading, the message is nevertheless worrisome.
The clinical implications of this study are significant. The NCCN has strict criteria for very low-risk prostate cancer and, even when including modern grading and extended biopsy sampling to these stringent criteria, African Americans fared significantly worse. AA race was an independent risk factor for upgrading at prostatectomy, adverse pathology, and higher pathologic risk score (CAPRA-S Ն 3). Thus, we believe that AA men considering active surveillance (AS) should be counseled that their disease-free outcomes may not parallel currently published oncologic outcomes from large AS cohorts. We also think these data highlight the need to re-examine AS criteria for AA men and to develop race-based risk classifiers.
The main limitation of our study is that it is a retrospective analysis of the experience of a single tertiary center. Though the men studied would be universally eligible for AS based on preoperative risk characteristics, this is not a report of an actual AS program. The median age of analyzed men was 58 years, whereas median age ranges from 61.9 to 70.3 years among patients in large AS cohorts. 4 This age difference is a potential confounder and highlights the importance of future studies to prospectively evaluate race-based AS outcomes.
Outcomes were not adjusted for pathologic tumor volume although this has been shown to not have prognostic significance after accounting for pathologic grade and surgical margin status. Furthermore, data relevant to socioeconomic variables, frequency of screening, adherence to biopsy and treatment recommendations, and stringency of follow-up, which are all potential confounding factors, were unavailable for analysis. Nonetheless, the proportion of men lost to follow-up did not differ among the groups. Because the cohort is also largely referral-based, the series may be affected by a selection bias. However, this could be advantageous as the very low-risk groups we study may be more homogeneous with race-based outcome differences less prone to confounding factors. The strengths of our study are that it represents the largest reported cohort (n ϭ 256) of very low-risk African Americans who qualify for active surveillance. The primary results are derived from a cohort of men with extended biopsy sampling (Ն 10 cores) treated within the modern Gleason grading era (2004 to present). Thus, the results are closely applicable to contemporary men diagnosed with prostate cancer.
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In conclusion, this study shows a disparity in outcomes for AA men after RP by multiple metrics, even within a highly selected and contemporary cohort of very low-risk patients. This underscores the need to develop and use race-based risk classifiers when counseling patients about different management strategies. The results of our study do not support the universal rejection of active surveillance in AA men, but rather should promote future studies to address whether alternate race-specific surveillance entry criteria should be used for AA men to ensure oncologic parity with their white counterparts. Finally, the disparities in our study highlight the need for a detailed evaluation of AA tumors to uncover potentially distinct molecular phenotypes.
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